FDA
-
-
-
-
-
-
-
SCYNEXIS receives 180-day Nasdaq extension until June 15, 2026
-
-
-
-
-
-
-
SCYNEXIS receives $22 million from GSK to resolve MARIO study dispute
-
-
-
-
-
-
-
Scynexis (SCYX) resumes dosing in Phase 3 study of ibrexafungerp
-
-
-
-
-
-
-
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
SCYNEXIS Reports First Quarter 2024 Financial ResultsĀ and Provides Corporate Update
-
-
-
-
-
-
-
SCYNEXIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

